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Abstract
AIM
To identify metabolic signatures in urine samples from 
healthy and inflammatory bowel disease (IBD) children.
METHODS
We applied liquid chromatography and gas chroma-
tography coupled to targeted mass spectrometry (MS)-
based metabolite profiling to identify and quantify bile 
acids and host-gut microbial metabolites in urine samples 
collected from 21 pediatric IBD patients monitored three 
times over one year (baseline, 6 and 12 mo), and 27 
age- and gender-matched healthy children.
RESULTS
urinary metabolic profiles of IBD children differ 
significantly from healthy controls. Such metabolic 
differences encompass central energy metabolism, 
amino acids, bile acids and gut microbial metabolites. 
In particular, levels of pyroglutamic acid, glutamic 
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ORIGINAL ARTICLE
Urinary metabolic insights into host-gut microbial interactions 
in healthy and IBD children
Basic Study
Francois-Pierre Martin, Ming-Ming Su, Guo-Xiang Xie, Seu Ping Guiraud, Martin Kussmann, Jean-Philippe Godin, 
Wei Jia, Andreas Nydegger
the disease, pediatric patients suffer from additional 
growth failure and delayed puberty[3-5]. During 
this critical period, IBD children can suffer from 
malnutrition, which is related to reduced energy 
intake, malabsorption and thus loss of nutrients, and 
inflammation[3,6-9]. These factors mainly contribute 
to delayed growth and physiological maturation. 
Moreover, there is a great lack of knowledge on how 
to address metabolic and nutritional requirements in 
these children and adolescents[5]. The use of omics-
technologies for holistic molecular phenotyping over 
time can generate the data for a systems-level view 
of metabolic processes associated with growth and 
development of children in relation to the changing 
physiology in infancy and childhood[5]. 
Amongst the omic technologies, metabonomics 
enables the study of physiological regulatory processes 
through the simultaneous analysis of a large range 
of biochemical species[2,10-13]. The technology is based 
on either targeted or untargeted profiling of small 
biomolecular compounds in tissues and biological 
fluids, such as blood, urine or saliva. Metabolites 
profiles can be generated through the use of proton 
nuclear magnetic resonance (1H NMR) spectroscopy 
or mass spectrometry (MS) combined eventually 
with chromatographic separation. Recently, we have 
applied 1H NMR based profiling to urine samples from 
IBD and healthy matched children and highlighted 
differences related to central energy metabolism, as 
well as amino acid and gut microbial metabolism in 
relation to growth and disease activity[14]. In particular, 
we showed how specific metabolite patterns in urine 
could help monitoring metabolic status in relation to 
disease state. In the present study, we continue our 
metabolic exploration by targeting host-gut microbial 
metabolites in urine samples from the same children, 
including the aromatic amino acid and bile acid co-
metabolites - two well-established examples of 
transgenomic metabolic cross-talk. For this purpose, 
we applied liquid chromatography (LC) and gas 
chromatography (GC) coupled to MS-based metabolite 
profiling. We here report urinary metabolic phenotypes 
specific to IBD children compared to healthy matched 
controls. Advanced clinical and anthropometric 
phenotyping was also performed on these IBD children 
over the course of one year of standard-care disease 
management (0, 6 and 12 mo) to identify relationships 
between biochemical processes and anthropometric 
phenotypes.
MATERIALS AND METHODS
Ethical considerations
This clinical study was approved by the Ethical Committee 
of the University of Lausanne, Switzerland (protocol 
69/10), and conducted in the Pediatric Gastroenterology 
outpatient clinic of the University Hospital of Lausanne, 
Switzerland. Informed written consent was obtained 
from the patients and their parents.
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acid, glycine and cysteine, were significantly higher in 
IBD children in the course of the study. This suggests 
that glutathione cannot be optimally synthesized and 
replenished. Whilst alterations of the enterohepatic 
circulation of bile acids in pediatric IBD patients is 
known, we show here that non-invasive urinary bile acid 
profiling can assess those altered hepatic and intestinal 
barrier dysfunctions.
CONCLUSION
The present study shows how non-invasive sampling 
of urine followed by targeted MS-based metabonomic 
analysis can elucidate and monitor the metabolic status 
of children with different GI health/disease status.
Key words: Pediatric; Metabolism; Phenotype; Growth; 
Inflammatory bowel disease; Crohn’s disease; ulcerative 
colitis
© The Author(s) 2017. Published by Baishideng Publishing 
Group Inc. All rights reserved.
Core tip: Despite the limited number of subjects, the 
longitudinal experimental design with a healthy reference 
group reveals insights into childhood metabolic status 
in relation to growth and disease. Metabolite profiling 
of urine samples collected non-invasively enables 
identification and monitoring of biochemical signatures 
linked to metabolic and nutritional requirements in 
pediatric populations with inflammatory bowel disease 
(IBD). In the present study, a distinct biochemical 
process related to glutathione, glycine and bile acid 
metabolism distinguished children with IBD from healthy 
matched controls.
Martin FP, Su MM, Xie GX, Guiraud SP, Kussmann M, Godin 
JP, Jia W, Nydegger A. Urinary metabolic insights into host-
gut microbial interactions in healthy and IBD children. World J 
Gastroenterol 2017; 23(20): 3643-3654  Available from: URL: 
http://www.wjgnet.com/1007-9327/full/v23/i20/3643.htm  DOI: 
http://dx.doi.org/10.3748/wjg.v23.i20.3643
INTRODUCTION
The use of systems biology-oriented technologies 
(e.g., metabonomics, proteomics, genomics and 
microbiomics) redefines disease understanding and 
phenotyping of clinical characteristics in medical 
disorders such as in gastrointestinal deregulations[1,2]. 
This is particularly relevant for inflammatory bowel 
disease (IBD), where a systems-level approach of the 
pathogenesis can inform novel, integrated multiple 
pathway- therapies and contribute to the development 
of personalized disease management[2]. 
The prevalence of IBD has markedly increased 
over the years, with 25% of the population developing 
the disease during childhood and adolescence[2,3]. In 
addition to the clinical and immunological features of 
Recruitment of participants
Eligible patients were aged between 10 and 18 years old, 
with a diagnosis of Crohn’s disease (CD) or ulcerative 
colitis (UC), confirmed according to international 
criteria[15]. IBD subjects were assessed at baseline 
(T0), after 6 (T6) and 12 mo (T12), respectively. All 
patients were in remission and underwent therapeutical 
management of the disease according to recommended 
drugs. To be noted that none was treated with enteral 
nutrition and no endoscopy was performed to assess 
mucosal inflammation. Control healthy subjects were 
recruited among the general pediatric population. They 
were matched for age, pubertal stage and gender to the 
IBD subjects. They had neither chronic inflammatory 
disease nor family history of inflammatory bowel. 
Anthropometric and clinical data and urine samples for 
metabolic analyses were collected at each time point. 
Anthropometric assessment
Body weight, height and BMI were measured under 
standard clinical practice, as previously reported[14]. 
Height velocity was calculated as the amount of growth 
in centimeters divided by the time interval between 
measurements in years. All values were expressed in 
z-scores[16,17]. Pubertal stage was assessed according 
to Tanner score[18].
Body composition 
Bioimpedance analysis (BIA) was performed using 
Body Impedance Analyser Akern (Florence, Italy), as 
previously reported[14]. Fat free mass in kg (FFM) was 
then calculated using the software BodyGram Pro® 
supplied by the manufacturer [which uses weight, age, 
and an impedance index (height2/resistance)][19,20]. 
Percentage of FFM (%FFM) was calculated by dividing 
FFM with the body weight of the subject expressed in kg.
Disease activity in patients with IBD
Disease activity was scored using the Pediatric Crohn’s 
Disease Activity Index (PCDAI)[21] for CD, a 100 point 
scale where a score > 30 indicates severe disease, and 
the Pediatric Ulcerative Colitis Activity Index (PUCAI)[22] 
for UC, a 85 points scale where a score > 35 indicates 
severe disease. Remission was defined as PCDAI or 
PUCAI score lower than 10. No endoscopic control was 
performed since all patients were in remission.
Blood and stool markers
Inflammatory markers [Erythrocyte Sedimentation 
Rate (ESR), C-Reactive Protein (CRP)], urea, and 
growth factors [Insulin-like Growth Factor 1 and 
Insulin-like Growth Factor-Binding Protein 3, expressed 
in z-scores] were obtained after a fasting period of at 
least 6 h. Fecal calprotectin was measured and a cut-
off value of 275 µg/g was set to determine possible 
relapse of disease[23]. 
Dietary intake
All subjects underwent a 24-h food recall with the help 
of a questionnaire showing pictures of different sizes of 
plates for the different foods with the same examiner 
(dietician TC). Qualitative and quantitative analyses 
were made using the software Prodi 5.8 Expert. Daily 
intake was expressed as kcal per day. 
Resting energy expenditure
Resting energy expenditure (REE, kcal) was measured 
using Quark RMR (Cosmed, pulmonary function equip-
ment, Delta Medical, Italy), as previously reported[14]. 
Sample collection
Morning spot urine samples were collected at baseline 
for all subjects, at the 6-mo and 12-mo visit for IBD 
patients only. Urine samples (1 mL) were collected by 
means of sterile plastic tubes, and stored at -80 ℃, 
prior to analysis. 
Bile acid analysis
Chemicals: All of the 57 bile acid standards were 
obtained from Steraloids Inc. (Newport, RI) and 
TRC Chemicals (Toronto, ON, Canada), and 9 stable 
isotope- labeled standards were obtained from C/D/N 
Isotopes Inc. (Quebec, Canada) and Steraloids Inc. 
(Newport, RI). 
Methanol (Optima LC-MS), acetonitrile (Optima LC-
MS) and formic acid (Optima LC-MS) were purchased 
from Thermo-Fisher Scientific (FairLawn, NJ). Ultrapure 
water was produced by a Mill-Q Reference system 
equipped with a LC-MS Pak filter (Millipore, Billerica, 
MA).
Sample preparation: At the time of analysis, samples 
were thawed on ice-bath to diminish biochemical 
degradation. 100 µL of urine or standard solution 
of a bile acid-free matrix was directly lyophilized to 
dry powder using a freeze dryer. The residue was 
reconstituted in 50 µL of mobile phase B (acetonitrile/
methanol = 95/5, v/v) and 25 µL of mobile phase A 
(water with formic acid, pH = 3.25), and centrifuged 
at 13500 g and 4 ℃ for 20 min. The supernatant was 
transferred to a 96-well plate for LC-MS analysis and 
the injection volume was 10 µL.
Data generation and analysis: An ultra-performance 
liquid chromatography coupled to tandem mass 
spectrometry (UPLC-MS/MS) system (ACQUITY UPLC-
Xevo TQ-S, Waters Corp., Milford, MA) was used to 
quantitate bile acids in the human urine samples based 
on our previously published protocols[24,25]. The raw 
data was processed using the TargetLynx application 
manager (Waters Corp., Milford, MA) to obtain 
calibration equations and the measured concentration 
of each bile acid in the samples. The quality control 
samples were prepared with the addition of bile acid 
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(30 m × 0.25 mm i.d., 0.25 µm film thickness; 
(5%-phenyl)-methylpolysiloxane bonded and cross-
linked; Agilent JW Scientific, Folsom, CA) , with helium 
as the carrier gas at a constant ﬂow rate of 1.0 mL/min. 
The solvent delay time was set to 2.5 min. The opti-
mized temperature gradient was the following: 45 ℃ 
held for 1 min, then increased at a rate of 20 ℃/min up 
to 260 ℃ and 40 ℃/min to 320 ℃/min, then held there 
for 2 min. The total time of analysis was 15.25 min. 
The temperature of injection, transfer interface and ion 
source were set to 270, 270 and 220 ℃, respectively. 
Electron impact ionization (70 eV) at full scan mode 
(m/z 38-650) was used. The acquisition rate was 20 
spectra/s.
Data processing: Non-processed MS files from GC/
TOFMS analysis were exported in NetCDF format to 
ChromaTOF (v4.50, Leco Co., CA, United States) and 
subject to the following processing including baseline 
correction, smoothing, noise reduction, deconvolution, 
library searching, and area calculation. Compound 
identification was performed by comparing both MS 
and Kovats-RI with reference standards in author-
constructed two alkyl chloroformates derivatives 
databases, with a similarity of more than 70%. 
Statistical analysis
Chemometric analysis was performed on clinical 
and metabonomics data using the software pack-
age SIMCA-P+ (version 12.0, Umetrics AB, Umeå, 
Sweden). Principal component analysis (PCA) and 
a modification of Partial Least Squares Regression 
(PLSR) that removes all information orthogonal to 
the response variable during the fitting process were 
employed. This variant, Orthogonal Projection to 
Latent Structures (O-PLS)[28] provides sparser models 
(improving their interpretability) with the same degree 
of fit as PLSR. For group comparison, multivariate 
data analysis was performed using O-PLS-discriminant 
analysis (OPLS-DA). To highlight the weight of 
individual variables in the model, Variable Importance 
in the Projection (VIP) was used, with a value above 
1 used as a threshold by convention. In addition, a 
Pearson correlation coefficient with a p-value significant 
at 95% confidence interval (e.g., with n = 46, r = 
0.40). Metabolic pathway analysis was conducted by 
performing a metabolite set enrichment analysis, using 
the web-based MetaboAnalyst 3.0 tool[29], to the list of 
influential metabolites obtained through multivariate 
data analysis.
RESULTS
Clinical and metabolite parameters of IBD and healthy 
subjects
The patient information has been reported previ-
ously[14]. Briefly, the study population was composed 
of 21 pediatric IBD patients and 27 age and gender 
stock solutions to blank matrix at a final concentration 
of 10, 100, or 1000 nmol/L. The quality control sam-
ples (four QCs in a 96-well plate) were prepared 
along with the real samples, and injected at regular 
intervals to allow evaluating overall process variability 
and monitoring platform performance. Each kit plate 
is ideal for the analysis of 84 samples, 8 calibrators 
(CAL0 = blank matrix), and 4 QCs (QC1 = 10 nmol/L, 
QC2 and QC3 = 100 nmol/L, and QC4 = 1000 nmol/
L). The noise baseline was established from reagent 
blank measurement and any metabolite with signal to 
noise ratio ≤ 3.0 is rejected from statistical analysis. 
The relative standard deviation (RSD) for the lower 
concentration metabolites in the reference standard 
mixture was less than 30% and the RSD for the higher 
concentration metabolites was better than 15% for 
each batch of sample analysis (100 injections for LC-
MS analysis). 
GC-MS based metabonomics
Chemicals: The derivatization reagents methyl and 
ethyl chloroformate, as well as HPLC grade solvents 
including methanol, ethanol, chloroform and pyridine 
were purchased from Sigma-Aldrich (St. Louis, MO, 
United States). Sodium hydroxide, sodium bicarbonate 
and anhydrous sodium sulfate were of analytical grade 
and obtained from JT Baker Co. (Phillipsburg, NJ). All 
standard compounds were commercially purchased 
from Sigma-Aldrich and Nu-Chek Prep (Elysian, MN, 
United States). Ultrapure water was produced by 
Milli-Q system (Millipore, Billerica, MA).
Extraction of metabolites from human urine: 
Urine samples were thawed on ice and prepared 
as follows: urine sample (100 µL) was added into a 
silanized glass vial and lyophilized directly under low 
temperature (-40 ℃) by a Labconco freeze-dryer. The 
solids from urine samples after lyophilization process 
were sealed and stored at -80 ℃ for subsequent 
automated derivatization assay.
Automated chloroformate derivatization and 
GC/MS analysis: The sample derivatization protocols 
with MCF and ECF was based on the method described 
by Villas-Bôas et al[26] and our previously published 
procedures[27], with minor modifications. For routine 
large-scale sample analysis, sample derivatization 
and all liquid handling were performed by a commer-
cially available robotic workstation (GERSTEL MPS 
Autosampler). 
Gas chromatography/time-of-flight mass spec-
trometry analysis: Samples were randomly analyzed 
by GC/TOFMS (Agilent 6890N gas chromatography 
coupled with a LECO Pegasus HT time-of-ﬂight mass 
spectrometer) using our optimized conditions in this 
study. One microliter of each derivatized sample was 
injected splitless into a DB-5 ms capillary column 
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Table 1  Urinary metabolite overview in healthy and inflammatory bowel disease children at baseline
Metabolites Healthy IBD baseline P  value
2-hydroxybutyric acid   324.2 ± 228.5    401.9 ± 306.8 0.335
3-(3-hydroxyphenyl)-3-hydroxypropanoic acid     85.1 ± 242.2    240.6 ± 488.6 0.168
3-aminoisobutanoic acid      7278 ± 8267.9    12302.4 ± 15388.8 0.166
3-hydroxyisovaleric acid   12675.2 ± 14366.2  13929.9 ± 6198.6 0.722
3-hydroxyphenylacetic acid   6618.8 ± 7906.4    3579.7 ± 4269.6 0.134
3-methyl-2-oxovaleric acid 12049.5 ± 5596.6  13764.2 ± 4303.2 0.269
4-hydroxybenzoic acid 1659.4 ± 835.8  1660.6 ± 735.9 0.996
4-hydroxycinnamic acid      1749 ± 2142.3    4655.3 ± 5127.8 0.013
Adipic acid   5757.5 ± 3488.3    6806.6 ± 6403.6 0.485
Alpha-hydroxyisobutyric acid   7514.4 ± 4562.7  10645.1 ± 5098.4 0.036
Aminoadipic acid   23462.2 ± 13757.6       24927 ± 13309.2 0.722
Beta-alanine   3554.8 ± 2690.1    3730.4 ± 2705.5 0.830
Butyric acid      594 ± 329.1 754.4 ± 551 0.230
Caproic acid   337.3 ± 393.0    423.4 ± 412.3 0.480
Caprylic acid   113.7 ± 233.6    114.2 ± 335.3 0.996
Cis-aconitic acid    126743 ± 94692.1       217610 ± 154442.2 0.019
Citraconic acid 1487.4 ± 719.3  1877.1 ± 529.1 0.051
Citramalic acid      13454 ± 11088.9    29200.5 ± 23835.6 0.005
Citric acid   1521627.7 ± 1117692.9    2010896.5 ± 1470323.3 0.211
Dodecanoic acid        76 ± 118.3      95.1 ± 230.1 0.718
Dopamine   25594.1 ± 15600.7  46132.8 ± 4070.5 0.000
Ethylmethylacetic acid   354.4 ± 161.6       300 ± 108.3 0.208
Fumaric acid   4447.5 ± 5258.8    8002.2 ± 5704.2 0.036
Gamma-aminobutyric acid   8011.9 ± 2433.5    9501.4 ± 2144.3 0.038
Glutaric acid   6350.9 ± 2956.9 8011.9 ± 3153 0.077
Glyceric acid   24294.2 ± 44555.4    34244.8 ± 54085.6 0.503
Glycine   90591.2 ± 73998.7       150330 ± 121868.4 0.048
Glycolic acid   85357.2 ± 57207.8    98641.7 ± 50868.8 0.424
Hippuric acid   579641.8 ± 409879.0    435904.9 ± 374381.5 0.234
Homogentisic acid   395731.6 ± 236443.5  706581.6 ± 61533.7 0.000
Indoleacetic acid   58737.6 ± 40343.9    107584.7 ± 107498.1 0.040
Isocitric acid   418285.5 ± 291898.4    767013.4 ± 476267.9 0.004
Isovaleric acid     96.7 ± 125.3      53.8 ± 103.4 0.228
Itaconic acid   7961.3 ± 6523.3    12949.6 ± 11408.9 0.071
L-2-hydroxyglutaric acid 14028.4 ± 7911.3    25645.4 ± 16050.4 0.003
L-alanine   26378.1 ± 18928.9    36445.6 ± 16618.3 0.070
L-alpha-aminobutyric acid   1777.6 ± 1093.0    1826.9 ± 1158.2 0.885
L-asparagine   16684.8 ± 15672.4    25642.5 ± 14904.9 0.059
L-aspartic acid 2801.2 ± 833.5 3708.1 ± 1242 0.005
L-cysteine   7833.5 ± 5012.7     12771 ± 4681.6 0.002
L-glutamic acid   18551.2 ± 13284.8    29044.7 ± 18203.4 0.030
L-histidine   300484.2 ± 313800.2       328182 ± 163648.8 0.726
L-isoleucine 1874.2 ± 954.0    3149.4 ± 1492.8 0.001
L-leucine   4028.1 ± 3120.4    5677.4 ± 4266.7 0.141
L-lysine   38409.7 ± 46071.6    46194.7 ± 36720.6 0.545
L-methionine 1236.4 ± 696.3    2195.1 ± 1206.4 0.002
L-phenylalanine   18545.8 ± 14394.6       26167 ± 13952.9 0.082
L-proline 1131.5 ± 512.2    2020.9 ± 1099.8 0.001
L-tryptophan   26500.2 ± 13737.3    33639.1 ± 12697.3 0.082
L-tyrosine   63971.6 ± 55716.2    84163.3 ± 63553.6 0.264
L-valine   4892.5 ± 2641.4    7343.2 ± 3296.4 0.008
Malonic acid      493 ± 486.4    663.3 ± 547.4 0.277
Methylsuccinic acid 1655.6 ± 861.4    2484.1 ± 1188.1 0.009
N-acetyltryptophan   82232.1 ± 58726.0  112567.4 ± 56382.5 0.088
Nicotinic acid   1293.3 ± 1311.8 2104.1 ± 1204 0.039
Ornithine   7948.8 ± 2592.9  11968.9 ± 4307.9 0.000
Ortho-hydroxyphenylacetic acid 1265.1 ± 770.7    1915.5 ± 1233.6 0.035
Oxoglutaric acid   23844.7 ± 20947.4    34260.9 ± 33676.2 0.209
Phenol   266.1 ± 168.1       282 ± 165.2 0.753
Phenylacetic acid   3055.4 ± 2506.3    5635.2 ± 5749.6 0.048
Phenyllactic acid     729.1 ± 1365.9    2726.7 ± 2958.9 0.004
P-hydroxyphenylacetic acid   8991.4 ± 5587.6  16438.3 ± 9973.0 0.003
Pimelic acid      2203 ± 1453.7    3343.5 ± 1728.2 0.021
Pyroglutamic acid   39396.7 ± 14482.8    52204.6 ± 19506.9 0.015
Salicyluric acid   3342.8 ± 1712.7    4135.9 ± 1498.5 0.112
Suberic acid   8538.8 ± 5594.7  12987.5 ± 5378.1 0.010
Succinic acid   23748.9 ± 18864.3    34383.7 ± 30189.9 0.154
Tartaric acid   5156.1 ± 9387.3    11376.5 ± 27499.5 0.291
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matched healthy children. IBD children were moni-
tored over one year period, with a baseline visit, 
and follow-up visits after 6 and 12 mo. CD patients 
showed lower z-scores for body weight, height, BMI 
and resting energy expenditure at baseline and at 
follow-up visits[14]. Targeted MS metabolic profiling 
detected and quantified 69 metabolites by GC-MS 
and 30 bile acid species in urine. We report in Table 
1 the urinary concentrations of all the metabolites 
at baseline for health and IBD children. Using this 
set of 99 metabolites, we have applied a Metabolite 
Set Enrichment Analysis[29] to summarize the main 
metabolic pathways captured by our systems approach. 
As reported in Figure 1, the analysis provides a 
comprehensive approach to generate insights in 
relation to protein biosynthesis, bile acid biosynthesis, 
aspartate, alanine, glutathione, urea, ammonia and 
citric acid (TCA) cycles. 
Urine biochemical composition illustrates metabolic 
differences between IBD and healthy children
Due to sample dilution, the urine sample from hone 
healthy control was discarded from analysis by MS 
metabonomics. Initial inspection of the main source 
of variations between the samples was performed 
using principal component analysis (PCA). A model 
was generated using four principal components, 
explaining 30%, 8%, 6% and 4% of the total variance, 
respectively. The sources of variance captured by the 
third and fourth components highlighted a separation 
of the urine of healthy children from the IBD patients, 
irrespective of their time of collection.
Using OPLS-DA, we first assessed the occurrence 
of urinary signatures discriminating the urine samples 
from healthy subjects and IBD patients. A first OPLS-
DA model generated on urine samples collected, 
with one predictive and one orthogonal component, 
described statistically robust metabolic differences 
at baseline. This is observed through the model 
parameters R2X = 0.37, R2Y = 0.72, Q2Y = 0.47, 
where R2X is the explained variance in the urine 
metabolic profile, R2Y the explained group variance 
and Q2Y an indicator of mode robustness. We further 
tested the reproducibility of the metabolic differences 
by comparing the urine collected from IBD patients 
after 6 and 12 mo of standard disease management 
Vanillic acid   2838.1 ± 5734.4   3091.8 ± 3028.7 0.861
12_ketoLCA 11.5 ± 2.4 13.5 ± 4.5 0.072
3_DHCA   13.4 ± 11.9      17 ± 15.7 0.396
7_DHCA   145.5 ± 276.1   267.1 ± 439.7 0.267
7_ketoLCA 10.9 ± 2.9 13.6 ± 7.2 0.093
Beta-CA   12.9 ± 10.4   26.1 ± 27.0 0.029
Beta-UCA   42.1 ± 93.8   114.8 ± 168.0 0.074
CA   182.3 ± 237.0      266 ± 322.5 0.327
CDCA 21.9 ± 9.7   24.9 ± 11.2 0.346
CDCA_24GLN   79.6 ± 49.1      168 ± 151.2 0.008
CDCA_3GLN   64.1 ± 45.2   149.1 ± 105.5 0.001
DCA   45.2 ± 28.7   40.2 ± 31.0 0.588
GCA   84.4 ± 43.2   151.8 ± 162.6 0.051
GCDCA   39.8 ± 20.6   51.3 ± 25.1 0.105
GDCA   34.5 ± 33.4   30.4 ± 15.9 0.627
GHCA   36.7 ± 17.6   49.4 ± 41.5 0.171
GHDCA 14.4 ± 2.6 12.3 ± 0.6 0.002
GLCA   8.4 ± 5.7   4.8 ± 4.2 0.026
GUDCA   15.5 ± 17.5   39.5 ± 47.9 0.025
HCA 10.3 ± 1.5 10.5 ± 1.5 0.768
HDCA   17.1 ± 35.3   15.2 ± 10.2 0.820
LCA 19.1 ± 6.6   22.4 ± 32.6 0.621
LCA_S   22.5 ± 11.9   22.6 ± 22.2 0.989
NORCA   154.3 ± 116.0   181.4 ± 133.4 0.476
NORDCA   9.2 ± 1.5   9.3 ± 0.4 0.679
TCA 24.6 ± 8.2      26 ± 11.9 0.652
TCDCA 23.4 ± 7.7 23.4 ± 5.6 0.99
THCA 13.7 ± 3.0   18.4 ± 11.4 0.052
TUDCA   8.2 ± 1.6      9 ± 1.2 0.099
UCA   108.2 ± 135.4   268.4 ± 310.0 0.024
UDCA 11.6 ± 1.4 13.1 ± 2.0 0.008
Metabolite data are reported as mean ± SD of their urinary concentrations, in ng/mL for GC-MS metabolites, and nmol/L for the bile acids. P value from 
standard t-test is reported as a qualitative indicator for metabolic variations between the two groups of children. 12-KetoLCA: 12-ketolithocholic acid; 
3_DHCA: 3-dehydrocholic acid; 7_DHCA: 7-dehydrocholic acid; 7_KetoLCA: 7-ketolithocholic acid; 3βCA: 3β-Cholic acid; βUCA: β-ursocholic acid; 
CA: Cholic acid; CDCA: Chenodeoxycholic acid; CDCA_24GLN: Chenodeoxycholic acid 24-Acyl-β-D-glucuronide; CDCA_3GLN: Chenodeoxycholic 
acid-3-β-D-glucuronide; DCA: Deoxycholic acid; GCA: Glycocholic acid; GCDCA: Glycochenodeoxycholic acid; GDCA: Glycodeoxycholic acid; 
GHCA: Glycohyocholate; GHDCA: Glycohyodeoxycholate; GLCA: Glycolithocholate; GUDCA: Glycoursodeoxycholic acid; HCA: γ-muricholic acid/
hyocholic acid; HDCA: α-hyodeoxycholic acid; LCA: Lithocholic acid; LCA_S: Lithocholic acid 3 sulfate; NORCA: Nor cholic acid; NORDCA: 3α,12α-
dihydroxynorcholanate/23-nordeoxycholic acid; TCA: Taurocholic acid; TCDCA: Taurochenodeoxycholic acid; THCA: Taurohyocholate; TUDCA: 
Tauroursodeoxycholic acid; UCA: Ursocholic acid; UDCA: Ursodeoxycholic acid.
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with the reference samples from the healthy children. 
The models generated with one predictive and one 
orthogonal component were significant at 6 mo (R2X 
= 0.36, R2Y = 0.67, Q2Y = 0.41) and at 12 mo (R2X = 
0.38, R2Y = 0.73, Q2Y = 0.47).
Examination of the three models resulted in the 
identification of consistent urinary metabolic differences 
between the group of healthy subjects and IBD 
patients. In Table 2, we report metabolites that were 
significantly different in at least two of the models with 
VIP > 1.0, and their corresponding Pearson correlation 
coefficient. These differences described variations in 
relation to glutathione metabolism (glycine, glutamate, 
pyroglutamate and cysteine), urea (fumarate, arginine, 
alanine, aspartate, and ornithine) and TCA (fumarate, 
isocitrate, 2-hydroxyglutaric acid, and methylsuccinic 
acid) cycles, catecholamines (dopamine and tyrosine), 
several amino acids (e.g., phenylalanine, tyrosine, 
proline, and glutamate), aromatic acid and bile acid 
bacterial co-metabolism. 
Whilst most of the metabolites appeared to be 
excreted in higher concentrations in IBD patients, only 
3 metabolites showed reduced concentrations, namely 
hippurate, 3-hydroxyphenylacetate and the bile acid 
glyco-hyodeoxycholic acid (GHDCA).
We further assessed if some urinary metabolites 
were specific to the few UC patients. OPLS-DA models 
were generated to compare the subjects at the different 
time points. The models generated with one predictive 
and two orthogonal components were significant at 
baseline (R2X = 0.42, R2Y = 0.94, Q2Y = 0.34), at 6 
mo (R2X = 0.48, R2Y = 0.94, Q2Y = 0.55) and at 12 
mo (R2X = 0.50, R2Y = 0.95, Q2Y = 0.55). Only three 
metabolites showed pattern differentiating UC from 
CD patients consistently over time, including higher 
urinary concentrations of deoxycholic acid (DCA), 
7-ketolithocholic acid and beta-ursocholic acid (βUCA) 
in urine from UC patients (Table 3).
Finally, we explored urinary metabolic signatures 
linked to clinical and anthropometric endpoints in 
the IBD population. An O-PLS regression approach 
was applied using cross-validation by subjects, since 
clinical and metabonomics data were generated 
from each subject at 3 different time points. Some 
relationships between urinary metabolite profiles and 
anthropometric features were modeled, but not in 
relation to disease index (Q2Y < 0) or inflammatory 
status (CRP, calprotectin, Q2Y < 0). Statistically 
significant associations were modeled in relation to BMI 
(R2X = 0.40, R2Y = 0.82, Q2Y = 0.35), BMI-z scores 
Figure 1  Summary plot for over representation analysis of urinary metabolites, using metabolite set enrichment analysis.
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(R2X = 0.40, R2Y = 0.83, Q2Y = 0.29), body weight 
(R2X = 0.43, R2Y = 0.74, Q2Y = 0.15), % of fat mass 
(R2X = 0.39, R2Y = 0.83, Q2Y = 0.36). A conservative 
approach was applied for selecting the most inﬂuential 
metabolites, namely using the VIP threshold > 1.0 and 
a r value significance at 95%CI (e.g., r > 0.265 or r 
< -0.265). A consolidated data overview is reported 
in Table 4 for the relevant anthropometric parameters 
and metabolites. Similar urinary metabolite patterns 
could be ascribed to the body composition parameters, 
including bile acids, amino acids and TCA cycle 
intermediates, as well as some dietary/gut microbial 
related metabolites (Table 4).
DISCUSSION
Our MS based metabonomics approach allowed to 
characterize further metabolite differences between 
IBD and healthy children, by providing complementary 
metabolite readouts into the central energy metabolic 
pathways, bile acids, glutathione and glycine meta-
bolism, which are discussed here after. 
Urinary bile acids as metabolic fingerprint of IBD 
phenotypes 
IBD is often associated with some variations in the 
enterohepatic circulation of bile acids[2,30,31]. Recently, 
Duboc et al[30] extensively discussed the connections 
between gut dysbiosis and bile acid metabolism in IBD, 
Table 2  Overview of influential metabolites discriminating healthy and inflammatory bowel disease patients
Metabolic pathways Metabolites Comparison healthy - IBD subjects at
Baseline 6 mo 12 mo
VIP r VIP r VIP r
Tca cycle Methylsuccinic acid 1.3  0.4 1.2  0.2 1.0  0.1
Fumaric acid 1.2  0.3 1.0  0.3 1.1  0.2
2-hydroxyglutaric acid 1.4  0.5 1.3  0.4 1.3  0.3
Isocitric acid 1.4  0.4 1.3  0.3 1.2  0.2
Glutathione metabolism Cysteine 1.5  0.5 1.2  0.3 1.4  0.4
Glycine 1.2  0.3 1.3  0.3 1.2  0.3
Glutamic acid 1.2  0.3 1.3  0.3 1.2  0.3
Pyroglutamic acid 1.3  0.4 1.3  0.3 1.0  0.1
Neurostransmitter metabolism Gamma-Aminobutyric acid 1.2  0.3 1.2  0.3 1.0  0.1
Dopamine 1.6  0.7 1.8  0.6 1.1  0.4
Homogentisic acid 1.6  0.7 1.8  0.6 1.1  0.4
Bacterial metabolism 3-hydroxyphenylacetic acid 1.3 -0.5 1.2 -0.4 1.1 -0.3
Hippuric acid 1.0 -0.3 1.2 -0.4 1.6 -0.5
Indoleacetic acid 1.3  0.4 1.3  0.4 1.0  0.1
4-hydroxyphenylacetic acid 1.3  0.5 1.1  0.3 1.0  0.2
Phenyllactic acid 1.1  0.4 0.6  0.2 1.4  0.5
Other Salicyluric acid 1.2  0.4 0.9  0.2 1.0  0.4
Dicarboxylic acid metabolism Suberic acid 1.3  0.5 1.5  0.5 1.1  0.3
Bile acids Beta-UCA 1.5  0.6 1.0  0.4 0.7  0.2
GUDCA 1.3  0.5 1.5  0.5 1.9  0.7
THCA 1.0  0.4 0.3  0.1 1.3  0.4
UDCA 1.4  0.6 1.7  0.6 1.8  0.6
GHDCA 1.3 -0.5 1.3 -0.5 1.0 -0.3
Amino acid metabolism Aspartic acid 1.3  0.4 0.8  0.2 1.4  0.4
Histidine 1.1  0.3 1.1  0.2 0.9  0.1
Isoleucine 1.5  0.4 1.6  0.4 1.3  0.2
Methionine 1.5  0.5 1.6  0.5 1.4  0.4
Phenylalanine 1.3  0.3 1.2  0.2 1.1  0.1
Proline 1.4  0.5 1.4  0.4 1.2  0.3
Tryptophan 1.2  0.3 1.2  0.2 1.1  0.2
Tyrosine 1.1  0.2 1.0  0.1 1.0  0.1
Valine 1.3  0.3 1.3  0.3 1.1  0.1
N-acetyltryptophan 1.2  0.3 1.2  0.2 1.1  0.2
Ornithine 1.4  0.5 1.7  0.5 1.7  0.5
Aminoadipic acid 1.0  0.0 1.2  0.3 1.1  0.1
IBD: Inflammatory bowel disease; TCA: Taurocholic acid; βUCA: Beta-ursocholic acid; GUDCA: Glycoursodeoxycholic acid; THCA: Taurohyocholate; 
UDCA: Ursodeoxycholic acid; GHDCA: Glycohyodeoxycholate.
Table 3  Overview of influential metabolites discriminating 
ulcerative colitis and Crohn’s disease patients
Comparison UC - CD 
subjects at metabolites
Baseline 6 mo 12 mo
VIP r VIP r VIP r
DCA 1.6 0.5 1.4 0.5 0.8 0.2
7-ketoLCA 1.1 0.3 1.2 0.4 1.8 0.5
Beta-UCA 0.3 0.1 2.0 0.7 1.0 0.3
UC: Ulcerative colitis; CD: Crohn’s disease; DCA: Deoxycholic acid; 
7_KetoLCA: 7-ketolithocholic acid; βUCA: Beta-ursocholic acid.
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and sub-sequent implication for the management of 
inﬂammatory conditions. For instance, the alterations 
in gastrointestinal transit time link to altered bacterial 
metabolism of primary and secondary bile acids[32]. 
This is reflected through higher concentrations of 
conjugated bile acids in the stools from active IBD 
patients, and concomitant decreased concentrations of 
secondary bile acids[30]. Bile acid malabsorption has also 
been reported in children with CD[33]. In our study, we 
report higher urinary excretion of taurohyocholic acid 
(THCA, a product of TCDCA metabolism by CYP3A4), 
ursodeoxycholic acid (UDCA, a product of CDCA by the 
gut microbiota and the liver), tauroursodeoxycholic 
acid (TUDCA, a taurine conjugate of UCDA), and 
βUCA. This signature most likely reﬂects the alteration 
of the bile acid metabolism in the digestive tract, 
as well as modulation of the metabolism of the 
secondary bile acids by the liver. Previous reports 
showed an alteration in most circulating bile acids in 
CD and UC patients[31]. In particular, UC patients were 
reported with higher amount of LCA and DCA, two 
secondary bile acids, which may relate to their higher 
urinary excretion in the urine as noted here. We also 
observed a strong association between BMI z-scores 
and urinary levels in several bile acids, a trend that 
was previously reported as well in plasma in other 
cohort studies[34]. Interestingly, the secondary bile 
acids UDCA and TUDCA are associated with the lower 
BMI z-score, whilst bacterial metabolites hippurate 
and 3-hydroxyphenylacetate are positively associated 
with the higher ones. Considering IBD children have 
overall higher urinary UDCA and TUDCA, lower urinary 
hippurate and 3-hydroxyphenylacetate, and lower 
BMI z-scores, the signature may be reﬂecting a higher 
degree of gastrointestinal deregulations with IBD. 
Pediatric IBD patients have altered urinary excretion of 
signaling molecules
Pediatric IBD patients also showed a higher urinary 
loss in dopamine, gamma-aminobutyric acid (GABA) 
and homogentisic acid. This pattern may be reﬂecting 
a disbalance in serotonin - dopamine metabolism, 
which is being studied in patient with CD[35]. Recent 
evidences tend to describe excessive synthesis with 
associated increased tissue levels of serotonin, leading 
to a perturbation of the molecular homeostasis 
with dopamine and catecholamines. In particular, a 
genetic defect of the OCTN1 and OCTN2 of the colon 
has been identified in patients with CD, resulting in 
altered transportation of monoamines of the serotonin-
dopamine system and their precursors[35]. The higher 
concentration in dopamine, closely related to higher 
levels of homogentisic acid (another product of 
tyrosine metabolism) may reﬂect this disbalance, yet 
serotonin metabolism could not be captured with our 
analytical approach in urine. Furthermore, the higher 
urinary loss of GABA may be reflecting the higher 
activity in the TCA cycle towards alpha-ketoglutarate 
Table 4  Overview of metabolites associated with anthropometric parameters
Metabolic 
pathways
Metabolites Anthropometric parameters
Fat mass % BMI BMI z-score Body weight
r VIP r VIP r VIP r VIP
TCA cycle L-2-hydroxyglutaric acid  0.41 1.57  0.22 1.23  0.29 1.36  0.14 1.07
Oxoglutaric acid  0.48 1.66  0.29 1.32  0.35 1.41  0.13 0.91
Succinic acid  0.39 1.50  0.17 1.12  0.24 1.24  0.10 0.98
Bacterial 
metabolism
3-hydroxyphenylacetic acid  0.44 1.49  0.27 1.20  0.29 1.22  0.23 1.07
Hippuric acid  0.32 1.27  0.27 1.27  0.28 1.26  0.19 1.03
Phenol  0.44 1.42  0.42 1.57  0.48 1.68  0.26 1.10
Bile acids 12_ketoLCA  0.34 1.13  0.41 1.53  0.40 1.40  0.39 1.48
DCA  0.48 1.62  0.48 1.82  0.50 1.76  0.52 2.02
GDCA  0.48 1.58  0.49 1.85  0.47 1.66  0.53 2.01
GHDCA  0.38 1.28  0.49 1.81  0.42 1.47  0.45 1.69
GLCA  0.19 0.87  0.32 1.28  0.30 1.17  0.43 1.69
LCA  0.35 1.16  0.37 1.40  0.34 1.20  0.41 1.57
NORDCA  0.37 1.25  0.45 1.65  0.44 1.54  0.57 2.13
TUDCA -0.12 0.81 -0.32 1.35 -0.31 1.27 -0.43 1.65
UCA -0.30 0.96 -0.38 1.39 -0.33 1.16 -0.35 1.42
UDCA -0.11 0.70 -0.42 1.60 -0.38 1.39 -0.44 1.65
Amino acid 
metabolism
Aminoadipic acid  0.36 1.41  0.22 1.20  0.25 1.23  0.17 1.06
L-Asparagine  0.26 0.89  0.34 1.33  0.36 1.30  0.27 1.21
L-Histidine  0.30 1.33  0.33 1.48  0.34 1.47  0.31 1.42
L-Methionine  0.31 1.39  0.16 1.16  0.24 1.29  0.09 1.03
L-Proline  0.30 1.35  0.15 1.13  0.23 1.27  0.10 1.06
L-Tryptophan  0.32 1.39  0.29 1.41  0.34 1.50  0.22 1.21
L-Tyrosine  0.27 1.29  0.23 1.26  0.26 1.32  0.15 1.07
N-acetyltryptophan  0.32 1.42  0.28 1.41  0.33 1.50  0.22 1.23
12-KetoLCA: 12-ketolithocholic acid; DCA: Deoxycholic acid; GDCA: Glycodeoxycholic acid; GHDCA: Glycohyodeoxycholate; GLCA: Glycolithocholate; 
LCA: Lithocholic acid; NORDCA: 3α,12α-dihydroxynorcholanate/23-nordeoxycholic acid; TUDCA: Tauroursodeoxycholic acid; UCA: Ursocholic acid; 
UDCA: Ursodeoxycholic acid.
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(AKG) and glutamate, and altered colonic epithelial cell 
metabolism of serotonin-dopamine[36].
IBD in pediatric populations links to perturbations in 
glycine metabolism
Another feature identified in the studied population 
is the occurrence of higher urinary levels of several 
metabolites involved in the glutathione metabolism, 
including pyroglutamic acid (PGA), glutamic acid, 
glycine and cysteine, which were significantly higher 
in IBD children in the course of the study. Since PGA is 
linked to glutathione turnover, the urinary pattern may 
reflect the higher requirement of the metabolism in 
glutathione to cope with oxidative stress and immune 
status[37,38]. In particular, higher urine PGA may indicate 
higher glutathione need concomitant to diminished 
glutathione utilization and/or deficient glutathione 
resynthesis. The higher urinary loss of cysteine, 
glycine and glutamic acid, the three main precursors 
for glutathione synthesis provides additional evidence 
that glutathione cannot optimally be resynthesized, 
and therefore is broken down and excreted in the urine 
via its constituent parts such as PGA. The observation 
of PGA may also point towards glycine deficiency[39], 
whilst the higher urinary excretion of many essential 
and non-essential amino acid mainly reﬂected higher 
protein breakdown related to higher metabolic 
requirements in IBD children. However, no statistically 
significant associations could be found between urinary 
metabolites and inflammatory endpoints (e.g., CRP, 
EST, calprotectin).
Moreover, it is well described, how before entering 
the urea cycle, glycine can be conjugated with benzoic 
acid to form hippurate, and be subsequently excreted 
in urine. An alternative pathway to excrete ammonia 
excess is through AKG to glutamic acid, glutamine and 
phenylacetylglutamine (PAG), which then exits the 
body via the urine. Glycine deficiencies would increase 
the demands on the urea cycle and the glutamate/AKG 
pathways. Moreover, the lower hippurate production 
may reflect this deficiency in glycine for specific 
metabolic processes. Previous studies reported that 
altered hippurate metabolic profile in IBD patients was 
not directly explain by variations in dietary intake or a 
deficit in the conjugation of benzoate to glycine in the 
kidney[40]. Moreover, our analysis describes a higher 
urinary excretion of salicyluric acid, a glycine conjugate 
of salicylic acid produced in the kidney via a pathway 
very similar to that of hippurate, suggesting selective 
requirement in glycine for metabolic functions. We 
previously discussed in the context of IBD[14], that 
carbamyl phosphate synthetase (CAD) - rate-limiting 
enzyme for the urea cycle - was identified as negative 
regulator of NOD2 and might be a pharmacologic 
target for CD therapies[41]. Our observations may 
provide additional evidence on the essential role of this 
pathway in case of higher metabolic requirements for 
glycine associated to malnutrition, higher requirement 
for glutathione, phase Ⅱ metabolism and/or growth 
and development in pediatric populations. 
Children with IBD show different energy and protein 
metabolic requirements
We previously reported and discussed how the pediatric 
IBD patients show the typical phenotype associated 
with growth failure and body weight loss[6,14,42]. In 
particular, we reported that our CD pediatric patients 
showed lower z-scores for body weight, body height, 
BMI and resting energy expenditure compared to 
healthy controls, which linked to lower concentrations 
in IGF-1 and IGFBP-3[14]. Our MS metabolomics 
approaches provided more detailed insights into 
the changes in protein and energy metabolites. IBD 
children showed a significant increase in the urinary 
content of several closely related intermediates of 
the TCA cycle (fumarate, isocitrate, 2-hydroxyglutaric 
acid, methylsuccinic acid). Our previous NMR analysis 
identified higher urinary PAG in IBD patients, which 
indicated a different energy metabolic status[14]. PAG 
is a major nitrogenous metabolite for which synthesis 
depends on the availability of glutamine, mainly 
generated in the Krebs cycle from AKG. Therefore 
the increase in isocitrate (precursor of AKG) may 
be functionally related to higher metabolic turnover 
for AKG. Moreover, we noted an increased excretion 
of a 2-hydroxyglutaric acid (Table 2), normally in 
molecular equilibrium with AKG, which brings further 
evidence for a specific increased metabolic flux 
towards AKG within TCA cycle. Whilst succinate does 
not show a significantly increased urinary excretion (in 
agreement with our previous NMR observations[14]), 
closely related metabolites, namely methylsuccinate 
and fumarate, had higher urinary levels which may 
describe a selective oxidation of aspartate, tyrosine 
and phenylalanine. 
Furthermore, the overall increased excretion in 
most amino acids and the sulfur containing amino 
acids cysteine and methionine (Table 2), indicates a 
different protein metabolism and handling of nitrogen 
in pediatric IBD patients when compared to healthy 
matched controls. Urinary metabolite patterns could 
be ascribed to body composition parameters, such a 
BMI, body weight and fat mass. Moreover, most of 
our IBD patients were in clinical remission, and whilst 
the patients tend to have lower z-scores for body 
weight, height and BMI at baseline, the higher the 
BMI z-scores during follow-up the better growth catch-
up for the patient. We here observed an association 
between higher BMI z-score and higher urinary 
content in key intermediates of the TCA cycle, namely 
succinate and AKG, amino acids (asparagine, histidine, 
methionine, tyrosine, proline). This signature may 
be associated with overall changes in protein and 
energy requirements related to body weight gain. Our 
observations with BMI z-scores are similar to recent 
observations in blood with the Framingham study[43]. 
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Strengths and weaknesses of the study
One main limitation of our study is the small number 
of subjects. However, the longitudinal design and the 
use of reference group of age- and gender match 
healthy children provide novel insights into childhood 
metabolic status in relation to growth and disease.
Future developments
We demonstrate that a direct analysis of urine - a 
biological sample that can be collected non-invasively 
and in a repeatable fashion - using targeted MS based 
metabonomics might provide metabolic insights 
complementary to more invasive blood and stool 
metabolic analysis, whilst offering an opportunity to 
monitor the metabolic status in relation to disease state. 
Here, we identified a peculiar metabolite signature 
related to bile acids, central energy and glutathione 
biochemical pathways, which should be further followed 
up in future studies. 
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Background
The prevalence of inflammatory bowel disease (IBD) has been increasing over 
the year, with 25% of the population developing the disease during childhood 
and adolescence. In the pediatric population, in addition to the clinical and 
immunological features of the disease, patients suffer of additional growth 
failure and delayed puberty. 
Research frontiers
There is a great lack of knowledge on how to address metabolic and nutritional 
requirements in children and adolescents. It is envisioned that the use of omics 
technologies can generate a system view of metabolic processes associated 
with the growth and the development of children in relation to the changing 
physiology. Metabonomics is a promising approach to explore physiological 
regulatory processes in human clinical research. 
Innovations and breakthroughs
In the present study, they applied targeted mass spectrometry based 
metabolite profiling to explore bile acids and host-gut microbial metabolites in 
urine samples from IBD and healthy matched children. Metabolic differences 
encompass central energy, amino acids, and bile acid metabolism. The authors 
showed that non-invasive urine bile acid profiling reflect altered hepatic and 
intestinal barrier dysfunctions, as previously reported through blood or stool 
metabolic profiling. Moreover, levels of pyroglutamic acid, glutamic acid, glycine 
and cysteine were significantly higher in IBD children in the course of the study. 
This suggests that glutathione cannot be optimally synthesized and replenished, 
rather it is broken down to its constituent parts and excreted through the urine. 
In addition, a perturbation of the urinary levels of several glycine conjugated 
metabolites, may associate with differential metabolic requirements in children. 
Applications
Non-invasive sampling of urine followed by targeted MS-based metabonomic 
analysis might elucidate and monitor the metabolic status of children in relation 
to disease state.
Peer-review
The excellent study gives a very good data set reflecting metabonomics in 
IBD children. Understanding the metabolic characteristics of pediatric patients 
with IBD compared to control is a key factor in diagnosis. The authors stuck to 
their specific hypothesis and eloquently presented their material. This opens 
the door for future trials looking at predictive modeling utilizing metabolomics 
and modifying various therapies to target patients with specific metabolic 
characteristics.
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